1.30

6.56% 0.08

After Hours: 1.32 0.02 +1.54%

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.30, with a volume of 74,943. It is up +6.56% in the last 24 hours and down -1.52% over the past month. Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Previous Close:

$1.22

Open:

$1.24

24h Volume:

74,943

Relative Volume:

0.72

Market Cap:

$44.70M

Revenue:

Net Income/Loss:

$-10.41M

P/E Ratio:

-3.8679

EPS:

-0.3361

Net Cash Flow:

$-3.69M

1W Performance:

+0.00%

1M Performance:

-1.52%

6M Performance:

-18.75%

1Y Performance:

-51.67%

1-Day Range:

$1.14

$1.3499

1-Week Range:

$1.14

$1.35

52-Week Range:

$1.05

$3.10

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Biotechnology (622)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2026-03-17

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.30	41.94M	0	-10.41M	-3.69M	-0.3361
VRTX Vertex Pharmaceuticals Inc	440.05	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	746.46	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	809.27	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.00	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	305.64	34.37B	5.36B	287.73M	924.18M	2.5229

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

Apr 10, 2026

Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn

Apr 10, 2026

Apr 06, 2026

Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn

Apr 06, 2026

Apr 05, 2026

TELO SEC FilingsTelomir Pharms 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 05, 2026

Apr 03, 2026

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire

Apr 03, 2026

Apr 01, 2026

Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld News

Apr 01, 2026

Telomir Pharmaceuticals Regains Nasdaq Compliance Following 2025 Annual Shareholders Meeting - Minichart

Apr 01, 2026

Telomir submits IND application for cancer drug candidate By Investing.com - Investing.com South Africa

Apr 01, 2026

Mar 31, 2026

Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks

Mar 31, 2026

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) Targeting Advanced Triple-Negative Breast Cancer - Minichart

Mar 31, 2026

Telomir Pharmaceuticals Submits IND for Telomir-1 in Advanced Triple-Negative Breast Cancer - National Today

Mar 31, 2026

Telomir Pharmaceuticals regains Nasdaq compliance after annual meeting - Investing.com

Mar 31, 2026

Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - Stock Titan

Mar 31, 2026

Telomir submits IND application for cancer drug candidate - Investing.com

Mar 31, 2026

Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan

Mar 31, 2026

Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC By Investing.com - Investing.com South Africa

Mar 31, 2026

Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC - Investing.com

Mar 31, 2026

Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC - TradingView

Mar 31, 2026

Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - Stock Titan

Mar 31, 2026

Mar 28, 2026

Telomir Shareholders Approve Equity Plan and Bylaw Changes - The Globe and Mail

Mar 28, 2026

Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 28, 2026

Telomir Pharmaceuticals 2026 Annual Meeting Results: Shareholder Votes, Amended Bylaws, and Incentive Plan Approval - Minichart

Mar 28, 2026

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today

Mar 28, 2026

Mar 27, 2026

Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union

Mar 27, 2026

Telomir Pharmaceuticals shareholders approve acquisition and bylaw changes - Investing.com UK

Mar 27, 2026

Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - Stock Titan

Mar 27, 2026

Pharma News: Should I trade or invest in Telomir Pharmaceuticals Inc2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn

Mar 27, 2026

Mar 25, 2026

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire

Mar 25, 2026

Mar 20, 2026

Setup Watch: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn

Mar 20, 2026

Mar 18, 2026

CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn

Mar 18, 2026

Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart

Mar 18, 2026

Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView

Mar 17, 2026

Telomir Pharmaceuticals (NASDAQ: TELO) details 2025 results, Telomir-1 plans and TELI merger - Stock Titan

Mar 17, 2026

US Market Recap: Will Unisys Corporation stock go up in YEAR2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Telomir Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 16, 2026

Mar 15, 2026

Winners Losers: Is Telomir Pharmaceuticals Inc a top pick in the sectorTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn

Mar 15, 2026

Mar 13, 2026

Risk Analysis: Can Genco Shipping Trading Limited be recession proofWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn

Mar 13, 2026

Mar 10, 2026

Trading Action: Is Telomir Pharmaceuticals Inc. a good ESG investmentQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn

Mar 10, 2026

Mar 06, 2026

Portfolio Recap: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn

Mar 06, 2026

Mar 05, 2026

Nasdaq Moves: Is Telomir Pharmaceuticals Inc a good ESG investment2025 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn

Mar 05, 2026

TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Mar 05, 2026

Mar 02, 2026

TELO Technical Analysis & ETF Price Forecast - Intellectia AI

Mar 02, 2026

Feb 27, 2026